The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MTST | +500% | -89.29% | -36.03% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +405% |
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients. The MenaCalc, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. The company was founded by Warren C. Lau in July 2009 and is headquartered in Boston, MA.
No news articles found for MetaStat.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
